AI Generated Image
Ozempic Is Quietly Becoming the Go-to Weight Loss Treatment for Teens
Gizmodo • • health
Key Points:
- GLP-1 medications like semaglutide (Ozempic, Wegovy) have seen a significant rise in use among teens and young adults treated for obesity, with usage increasing steadily since 2022 while bariatric surgery rates declined.
- The study analyzed over 200,000 medical records of U.S. patients aged 13 to 25 and found exclusive GLP-1 use grew from 88.2% to 96.1% between 2022 and early 2026, whereas bariatric surgery dropped from 11.6% to 3.7%.
- Despite endorsements from groups like the American Academy of Pediatrics for GLP-1 use in children over 12, some organizations remain cautious due to limited long-term safety data in younger populations.
- Researchers emphasize the need for evidence-based guidance on treatment sequencing and long-term outcomes, highlighting that GLP-1s should complement, not replace, comprehensive obesity care, with careful patient follow-up.
- Concerns exist about potential misuse of GLP-1s among youth, especially those with eating disorders, underscoring the importance of monitoring and managing these treatments responsibly.
